China Oncology ›› 2022, Vol. 32 ›› Issue (9): 818-826.doi: 10.19401/j.cnki.1007-3639.2022.09.009
• Article • Previous Articles Next Articles
ZHANG Jingchen(), LI Xin, LI Jiangtao, LI Haiping, CHEN Yanli, NIU Bing, QI Chuanchuan, YE Beibei
Received:
2022-01-06
Revised:
2022-03-25
Online:
2022-09-30
Published:
2022-10-24
Contact:
ZHANG Jingchen
CLC Number:
ZHANG Jingchen, LI Xin, LI Jiangtao, LI Haiping, CHEN Yanli, NIU Bing, QI Chuanchuan, YE Beibei. LINC02163 targeting miR-338-3p affects proliferation, invasion and migration of breast cancer cells[J]. China Oncology, 2022, 32(9): 818-826.
Tab. 2
Compare of c-Myc, MMP2, MMP9, E-cadherin, and N-cadherin protein expression in each group of MDA-MB-231 cells"
Group | MMP9/β-actin | MMP2/β-actin | c-Myc/β-actinc | N-cadherin/β-actin | E-cadherin/β-actin |
---|---|---|---|---|---|
Control | 1.62±0.22 | 1.23±0.17 | 1.50±0.25 | 1.04±0.10 | 0.43±0.06 |
sh-NC | 1.61±0.25 | 1.22±0.18 | 1.49±0.23 | 1.03±0.09 | 0.42±0.08 |
sh-LINC02163 | 0.68±0.03* | 0.33±0.06* | 0.52±0.08* | 0.21±0.05* | 1.40±0.21* |
sh-LINC02163+inhibitor-NC | 0.67±0.05 | 0.34±0.05 | 0.53±0.07 | 0.20±0.03 | 1.41±0.25 |
sh-LINC02163+miR-338-3p inhibitor | 1.28±0.12# | 1.15±0.10# | 1.40±0.22# | 0.89±0.08# | 0.70±0.11# |
[1] |
LIANG Y R, SONG X J, LI Y M, et al. LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis[J]. Mol Cancer, 2020, 19(1): 85.
doi: 10.1186/s12943-020-01206-5 pmid: 32384893 |
[2] |
ZHAO W Y, GENG D H, LI S Q, et al. LncRNA HOTAIR influences cell growth, migration, invasion, and apoptosis via the miR-20a-5p/HMGA2 axis in breast cancer[J]. Cancer Med, 2018, 7(3): 842-855.
doi: 10.1002/cam4.1353 |
[3] |
SHEN Y, PENG X W, SHEN C L. Identification and validation of immune-related lncRNA prognostic signature for breast cancer[J]. Genomics, 2020, 112(3): 2640-2646.
doi: S0888-7543(20)30065-3 pmid: 32087243 |
[4] |
QIN C L, JIN L F, LI J, et al. Long noncoding RNA LINC 02163 accelerates malignant tumor behaviors in breast cancer by regulating the microRNA-511-3p/HMGA2 axis[J]. Oncol Res, 2020, 28(5): 483-495.
doi: 10.3727/096504020X15928179818438 |
[5] |
TIAN Y, ZHOU J, ZOU Y F, et al. Upregulated long noncoding RNAs LINC02163 and FEZF1-AS1 exert oncogenic roles in colorectal cancer[J]. Anticancer Drugs, 2021, 32(1): 66-73.
doi: 10.1097/CAD.0000000000000975 |
[6] |
HE J J, WANG J, LI S C, et al. Hypoxia-inhibited miR-338-3p suppresses breast cancer progression by directly targeting ZEB2[J]. Cancer Sci, 2020, 111(10): 3550-3563.
doi: 10.1111/cas.14589 |
[7] | 周大为, 朱征涛, 靳明明, 等. hsa_circ_0070260靶向miR-27a-3p/Fbxw7对乳腺癌增殖,侵袭调控研究[J]. 重庆医学, 2020, 49(S1): 24-28. |
ZHOU D W, ZHU Z T, JI M M, et al. hsa_circ_0070260/miR-27a-3p/Fbxw7 regulates the proliferation and migration of breast cancer cells[J]. Chongqing Med, 2020, 49(S1): 24-28. | |
[8] |
MILLER K D, NOGUEIRA L, MARIOTTO A B, et al. Cancer treatment and survivorship statistics, 2019[J]. CA A Cancer J Clin, 2019, 69(5): 363-385.
doi: 10.3322/caac.21565 |
[9] |
XIU B Q, CHI Y Y, LIU L, et al. LINC02273 drives breast cancer metastasis by epigenetically increasing AGR2 transcription[J]. Mol Cancer, 2019, 18(1): 187.
doi: 10.1186/s12943-019-1115-y pmid: 31856843 |
[10] |
SHI Q F, LI Y D, LI S Y, et al. LncRNA DILA1 inhibits cyclin D1 inhibits cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer[J]. Nat Commun, 2020, 11: 5513.
doi: 10.1038/s41467-020-19349-w |
[11] |
DONG L M, HONG H S, CHEN X W, et al. LINC02163 regulates growth and epithelial-to-mesenchymal transition phenotype via miR-593-3p/FOXK1 axis in gastric cancer cells[J]. Artif Cells Nanomed Biotechnol, 2018, 46(sup2): 607-615.
doi: 10.1080/21691401.2018.1464462 pmid: 29893595 |
[12] |
MA J W, ZHANG L H, SHANG A Q, et al. LINC02163 promotes colorectal cancer progression via miR-511-3p/AKT3 axis[J]. Artif Cells Nanomed Biotechnol, 2020, 48(1): 961-968.
doi: 10.1080/21691401.2020.1773486 pmid: 32524841 |
[13] | 罗毅, 房晓瑜, 谢薇佳, 等. 长链非编码RNA LINC02163在肝细胞肝癌中表达上调并促进肝癌细胞迁移和侵袭[J]. 第三军医大学学报, 2020, 42(1): 81-87. |
LUO Y, FANG X Y, XIE W J, et al. Long non-coding RNA LINC02163 is up-regulated and promotes cell migration and invasion in hepatocellular carcinoma[J]. J Third Mil Med Univ, 2020, 42(1): 81-87. | |
[14] | 来旭, 范亚楠, 王瑞丰. LINC01106靶向miR-744-5p影响乳腺癌MDA-MB-231细胞增殖、迁移及侵袭[J]. 标记免疫分析与临床, 2021, 28(4): 577-582. |
LAI X, FAN Y N, WANG R F. LINC01106 affects the proliferation, migration and invasion of breast cancer MDA-MB-231 cells by targeting miR-744-5p[J]. Labeled Immunoass Clin Med, 2021, 28(4): 577-582. | |
[15] |
YU Y, LUO W, YANG Z J, et al. miR-190 suppresses breast cancer metastasis by regulation of TGF-β-induced epithelial-mesenchymal transition[J]. Mol Cancer, 2018, 17(1): 70.
doi: 10.1186/s12943-018-0818-9 pmid: 29510731 |
[16] | ZHENG J J, QUE Q Y, XU H T, et al. Hypoxia activates SOX5/Wnt/β-catenin signaling by suppressing miR-338-3p in gastric cancer[J]. Technol Cancer Res Treat, 2020, 19: 1533033820905825. |
[17] |
ZHANG L, DING F P. Hsa_circ_0008945 promoted breast cancer progression by targeting miR-338-3p[J]. Onco Targets Ther, 2019, 12: 6577-6589.
doi: 10.2147/OTT.S213994 |
[18] |
DUAN X, GUO G C, PEI X H, et al. Baicalin inhibits cell viability, migration and invasion in breast cancer by regulating miR-338-3p and MORC4[J]. Onco Targets Ther, 2019, 12: 11183-11193.
doi: 10.2147/OTT.S217101 |
[1] | Committee of Breast Cancer Society, Chinese Anti-Cancer Association, Breast Surgeons Committee of Surgeons Branch, Chinese Medical Doctor Association, Committee of Breast Cancer Society, Shanghai Anti-Cancer Association. Expert consensus on oncoplastic surgery of breast tumor and breast reconstruction (2022 edition) [J]. China Oncology, 2022, 32(9): 836-924. |
[2] | XIAO Yuling, ZHU Xiuzhi, JIANG Yizhou, SHAO Zhimin. New research advances and future prospect in precision treatment of triple-negative breast cancer [J]. China Oncology, 2022, 32(8): 669-679. |
[3] | QIU Pengfei, WANG Yongsheng. Precise regional management of breast cancer in the sentinel lymph node era: evolution and prospect [J]. China Oncology, 2022, 32(8): 680-687. |
[4] | ZHANG Yu, LIU Qiang. Advances of liquid biopsy in precision treatment of breast cancer [J]. China Oncology, 2022, 32(8): 688-697. |
[5] | ZHOU Wenbin, XIE Hui, DING Qiang, WANG Shui. New research progress of microwave ablation in the local precise treatment of early-stage breast cancer: the prospect of combined immunotherapy is promising [J]. China Oncology, 2022, 32(8): 698-704. |
[6] | LIU Yiming, FAN Lei, MO Miao, SHAO Zhimin, YU Keda. Factors-associated with short-term effect and long-term survival of ovarian function suppression in estrogen receptor positive breast cancer: a retrospective analysis [J]. China Oncology, 2022, 32(8): 705-711. |
[7] | XIAO Jialong, MO Miao, ZHOU Changming, WANG Zezhou, SHEN Jie, YUAN Jing, YU Keda, LIU Guangyu, WU Jiong, SHEN Zhenzhou, SHAO Zhimin, ZHENG Ying. The effect of the interaction between body mass index and age on the prognosis of breast cancer [J]. China Oncology, 2022, 32(8): 719-726. |
[8] | CHEN Anli, SHEN Haoyuan, YANG Shixiong, DENG Chunyan, HU Chaohua, LIU Hanzhong, WANG Shu, QIAN Fang. Predictive value of plasma long non-coding RNA H19 in neoadjuvant therapy for breast cancer [J]. China Oncology, 2022, 32(8): 727-735. |
[9] | LIU Qiang, FANG Yi, WANG Jing. Application progress of single-cell sequencing technology in breast cancer research [J]. China Oncology, 2022, 32(7): 635-642. |
[10] | QIAN Yao, LIU Feng. Research progress and prospects of neoadjuvant endocrine therapy for breast cancer [J]. China Oncology, 2022, 32(7): 643-649. |
[11] | JIA Xiaoqing, SUN Xiaoyin, JIANG Beiqi, MEI Zhangyi, FU Yun, ZHUANG Zhigang. Neddylation modification regulates lamin B1 expression in breast cancer [J]. China Oncology, 2022, 32(6): 535-541. |
[12] | LIU Jianlan, CHEN Daishi, HU Hong, ZHOU Dongxian, HU Jintao. Predictors of response to neoadjuvant treatment and changes to HER2 status in HER2-positive invasive breast cancer [J]. China Oncology, 2022, 32(5): 417-426. |
[13] | ZHANG Qian, FANG Xiaoyan, LIU Juan, LIU Jin, CHENG Leilei, SUN Jing. Study on the safety of simultaneous integrated boost and the importance of cardiac substructural dose assessment of hypofractionated radiotherapy after early left breast cancer breast-conserving surgery [J]. China Oncology, 2022, 32(5): 427-435. |
[14] | CAI Juan, CHEN Zhiqiang, ZUO Xueliang. CircSMARCA5 inhibits glycolysis and suppresses proliferation and invasion of gastric cancer cells through miR-4295/PTEN axis [J]. China Oncology, 2022, 32(4): 298-308. |
[15] | XU Bingqi, ZHANG Guoqiang. Advances in the diagnosis of pathological response by a second biopsy in breast cancer neoadjuvant therapy and their clinical significance [J]. China Oncology, 2022, 32(4): 335-342. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd